Abstract
The objective of the study was to evaluate the incidence, characteristics, treatment and outcome of acute megakaryoblastic leukemia (AMeL) in patients enrolled in GIMEMA trials. Between 1982 and 1999, 3603 new consecutive cases of AML aged over 15 years were admitted to GIMEMA trials. Of them, 24 were AMeL. The incidence of AMeL among AML patients enrolled in GIMEMA trials was 0.6% (24/3603). Diagnosis was based on morphological criteria. Out of 11 cytogenetic studies performed two presented chromosome 3 abnormalities. Twelve patients (50%) reached a CR, five (21%) died in induction and seven (27%) were unresponsive. The median duration of CR was 35 weeks (range 10–441). Seven patients underwent transplantation procedures (1 BMT, 4 aBMT, 2 aPBSCT). Four patients died in CR due to chemotherapy-related complications. Comparing the CR rate between AMeL and the other cases of AML enrolled in GIMEMA trials, no differences were observed. These results were mirrored for different age groups. The median survival was 40 weeks. At present, after a follow-up of a minimum of 2 years, only two patients are alive in CR, all the others having died. A 5-year Kaplan–Meier curve shows a disease-free survival of 17% and an actuarial overall survival of 10%. AMeL is a rare form of AML. The CR duration and the overall survival in this group of patients are very poor, even if similar to those observed in other AML. Furthermore, a high number of deaths in CR were observed. On the basis of these data, a specific therapeutic approach, possibly with innovative treatments, should be evaluated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Von Boros J, Korenyi A . Uber einen fall von akuter megakaryocyblasten-leukamie, zugleich einige bemerkungen zum Problem der akuten leukemie Z Klin Med 1931 118: 679–718
Gassmann W, Loffler H . Acute megakaryoblastic leukemia Leuk Lymphoma 1995 18 (Suppl. 1): 69–73
Pui C-H, Williams DL, Scarborough V, Jackson CW, Price R, Murphy S . Acute megakaryoblastic leukemia associated with intrinsic platelet dysfunction and constitutional ring 2 chromosome in a young boy Br J Haematol 1982 50: 191–200
San Miguel JF, Gonzalez M, Canizo MC, Ojeda E, Orfao A, Caballero MD, Moro MJ, Fisac P, Lopez Borrasca A . Leukemia with megakaryoblastic involvement: clinical, hematological and immunological characteristics Blood 1988 72: 402–407
Nichols CR, Hoffman R, Einhorn LH, Williams SD, Wheeler LA, Garnick MB . Hematologic malignancies associated with primary mediastinal germ-cell tumors Ann Intern Med 1985 102: 603–609
Nichols CR, Hoffman R, Glant MD, Goheen M . Malignant disorders of megakaryocytes associated with primary germ cell tumors Prog Clin Biol Res 1986 215: 347–353
Domingo A, Romagosa V, Callis M, Vivancos P, Guionnet N, Soler J . Mediastinal germ cell tumor and acute megakaryoblastic leukemia Ann Intern Med 1989 111: 539
Tallman MS, Neuberg D, Bennett JM, Francois CJ, Paietta E, Wiernik PH, Dewald G, Cassileth PA, Oken MM, Rowe JM . Acute megacaryocytic leukemia: the Eastern Cooperative Oncology Group experience Blood 2000 96: 2405–2411
Ruiz-Arguelles GJ, Lobato-Mendizabal E, San-Miguel JF, Gonzalez M, Caballero MD, Ruiz-Arguelles A, Orfao A, Gomez-Almaguer D, Vidriales B, Ruiz-Reyes G . Long-term treatment results for acute megakaryoblastic leukemia patients: a multicentre study Br J Haematol 1992 82: 671–675
Ribeiro RC, Oliveira MS, Fairclough D, Hurwitz C, Mirro J, Behm FG, Head D, Silva ML, Raimondi SC, Crist WM . Acute megakaryoblastic leukemia in children and adolescents: a retrospective analysis of 24 cases Leuk Lymphoma 1993 10: 299–306
Bernstein J, Dastugue N, Haas OA, Harbott J, Heerema NA, Huret JL, Landman-Parker J, LeBeau MM, Leonard C, Mann G, Pages MP, Perot C, Pirc-Danoewinata H, Roitzheim B, Rubin CM, Slociak M, Viguie F . Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group Leukemia 2000 14: 216–218
Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, Srivastava DK, Rubnitz JE, Bowman L, Pui CH, Ribeiro RC . Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience Blood 2001 97: 3727–3732
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C . Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French–American–British Cooperative Group Ann Intern Med 1985 103: 460–462
Petti MC, Mandelli F, Avvisati G, Covelli A, Amadori S, Liso V, Leone G, De Laurenzi A, Leoni P, Neri A . High-dose Ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA Eur J Haematol 1989 42: 24–31
Mandelli F, Vegna ML, Avvisati G, Amadori S, Spadea A, Cacciola E, Cantore N, De Laurenzi A, De Rosa C, Fioritoni G . A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA Ann Hematol 1992 64: 166–172
Resegotti L . Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience Leukemia 1992 6 (Suppl. 2): 72–75
Montillo M, Tedeschi A, Pagano L, Venditti A, Ferrara F, Fabris P, Martino B, Musso M, De Rosa G, Specchia G, Monaco M, Sparaventi G, Spadea A, Palmas A, Deplano W, Manna A, Melillo L, Miraglia E, Mirto S, Mandelli F . Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the Gimema Group. Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto Br J Haematol 2000 111: 334–337
Zittoun R, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Ferrini PR, Visani G, Caronia F, Stryckmans P . EORTC-GIMEMA AML8 protocol. A phase III study on autologous bone-marrow transplantation in acute myelogenous leukemia (AML) Leuk Lymphoma 1994 13 (Suppl. 1): 101
Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, Resegotti L, Caronia F, Leoni P, Petti MC . Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group Leukemia 1992 6 (Suppl. 2): 76–77
Zittoun R, Suciu S, De Witte T, Resegotti L, Liso V, Wikllemze R, Belharri A, Amadori S, Giustolisi G, Labar B, Fioritoni G, Rossi ferrini P, Leone G, Keating J, Fazi P, Dardenne M, Solbu G, Mandelli F . Comparison of three intercalating agents in induction and consolidation in acute myelogeneous leukemia (AML) followed by autologous or allogeneic transplantation: preliminary results of the EORTC-GIMEMA AML-10 randomized trial Blood 1999 94 (Suppl. 1): (Abstr. 2923)
Zucker-Franklin D, Yang JS, Grusky G . Characterization of glycoprotein IIb/IIIapositive cells in human umbilical cord blood: their potential usefulness as megakaryocyte progenitors Blood 1992 79: 347–355
Helleberg C, Knudsen H, Hansen PB, Nikolajsen K, Kjaersgaard E, Ralfkiaer E, Johnsen HE . CD34+ megakaryoblastic leukemic cells are CD38, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7? Leukemia 1997 11: 830–834
Ruiz-Arguelles GJ, Marin-Lopez A, Lobato-Mendizabal E, Ruiz-Arguelles A, Nichols WL, Katzman JA . Acute megakaryoblastic leukemia: a prospective study of its identification and treatment Br J Haematol 1986 62: 55–63
Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, Stollmann-Gibbels B, Zimmermann M, Harbott J . Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM study group Leukemia 1996 10: 1677–1686
Sastre JL, Ulibarrena C, Armesto A, del Rio D, Bello JA, Rodriguez M, Garcia Torremocha S, Vazquez O . Testicular granulocytic sarcoma as a form of relapse in ap patient with acute megacaryoblastic leukemia Sangre 1998 43: 248–250
Lorsbach RB, Folkerth RD, Pinkus GS . Relapse of acute myelogenous leukemia as a cerebellar myeloblastoma showing megacaryoblastic differentiation Mod Pathol 1999 12: 1186–1191
Mehta AB, Baughan AS, Catovsky D, Goldman JM, Johnson SA, Galton DA . Reversal of marrow fibrosis in acute megakaryoblastic leukaemia after remission-induction and consolidation chemotherapy followed by bone marrow transplantation Br J Haematol 1983 53: 445–449
Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, Dallorso S, Dufour C, Ferrara GB, Abbondandolo A, Dini G, Bacigalupo A, Cancedda R, Quarto R . Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients Exp Hematol 1999 27: 1460–1466
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Pagano, L., Pulsoni, A., Vignetti, M. et al. Acute megakaryoblastic leukemia: experience of GIMEMA trials. Leukemia 16, 1622–1626 (2002). https://doi.org/10.1038/sj.leu.2402618
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402618
Keywords
This article is cited by
-
Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3)
Diagnostic Pathology (2022)
-
SON inhibits megakaryocytic differentiation via repressing RUNX1 and the megakaryocytic gene expression program in acute megakaryoblastic leukemia
Cancer Gene Therapy (2021)
-
The Fetal-to-Adult Hematopoietic Stem Cell Transition and its Role in Childhood Hematopoietic Malignancies
Stem Cell Reviews and Reports (2021)
-
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
Nature Communications (2019)
-
Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2019)